

Generation of three iPSC lines from fibroblasts of a patient with Cohen syndrome

Pristyazhnyuk I.¹, Minina J.¹, Voinova V.^{2,3}, Safonova M.³, Lagarkova M.⁴, Menzorov A.^{1, 5*}

¹ Institute of Cytology and Genetics, SB RAS, Novosibirsk, Russia

² Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University, Moscow, Russia

³ The Mental Health Research Center, Moscow, Russia

⁴ Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

⁵ Novosibirsk State University, Novosibirsk, Russia

* menzorov@bionet.nsc.ru

Key words: iPSCs; Cohen syndrome

Motivation and Aim: Cohen syndrome is a rare autosomal recessive genetic disorder characterized by developmental delay, intellectual disability, microcephaly, neutropenia, dimorphisms, obesity, and ophthalmological and autistic spectrum disorders [1]. It is caused by homozygous or compound heterozygous variants in *VPS13B* gene. More than 200 pathological variants of the *VPS13B* gene in more than 1000 patients are currently registered [2]. The protein is localized on the Golgi complex. It has many domains and the function of some of them is still not clear. *VPS13B* is involved in lipid transport between cell membranes and is crucial for vesicular trafficking and autophagy. Previously we generated Cohen syndrome patient-specific induced pluripotent stem cells (iPSCs). The iPSC-derived neural stem cells and neurons had numerous ultrastructural abnormalities [3]. In this study, we produced iPSCs from fibroblasts of another Cohen patient that had *VPS13B* gene compound heterozygous variants with unknown clinical significance. A study of unknown variants may clarify the functions of *VPS13B* as well as the functional roles of its domains.

Methods and Algorithms: Generation and cultivation of the iPSC lines and methods of analysis were described previously [4]. Cell culture was performed at the Collective Center of ICG SB RAS “Collection of Pluripotent Human and Mammalian Cell Cultures for Biological and Biomedical Research” (<https://ckp.icgen.ru/cells/>; http://www.biores.cytogen.ru/brc_cells/collections/ICG_SB_RAS_CELL) supported by the state project FWNR-2022-0019.

Results: We have generated three iPSC lines from fibroblasts of the Cohen patient with previously unreported compound heterozygous variants (8:g.99766811A>G and 8:g.99859429G>A, HG38). Episomal vectors (Epi5) were used to reprogram fibroblasts. Sanger sequencing confirmed the presence of variants. The cell lines iCS-MCF3-1, iCS-MCF3-3, and iCS-MCF3-5 had normal karyotypes and expressed pluripotency markers OCT4, NANOG, and SSEA-4. Pluripotency was shown by analysis of embryoid bodies; they expressed gene markers of all three germ layers.

Conclusion: These iPSC lines could be used for the study of *VPS13B* functions and the impact of its variants on the cell function.

Funding: The study was supported by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2021-1063).

References

1. Seifert W., Holder-Espinasse M., Kühnisch J. et al. Expanded mutational spectrum in Cohen syndrome, tissue expression, and transcript variants of *COH1*. *Hum Mutat.* 2009;30(2):E404-E420. doi 10.1002/humu.20886
2. Douzgou S., Petersen M.B. Clinical variability of genetic isolates of Cohen syndrome. *Clin Genet.* 2011;79(6):501-506. doi 10.1111/j.1399-0004.2011.01669.x
3. Shnaider T.A., Khabarova A.A., Morozova K.N. et al. Ultrastructural abnormalities in induced pluripotent stem cell-derived neural stem cells and neurons of two Cohen syndrome patients. *Cells.* 2023;12(23):2702. doi 10.3390/cells12232702
4. Pristiyazhnyuk I.E., Meshcheryakov N.I., Nikitina T.V. et al. Generation of induced pluripotent stem cell line iTAF15Xsk4 from fibroblasts of a patient with microdeletion at Xq24. *Russ J Dev Biol.* 2023;54:358-364. doi 10.1134/S1062360423060073